Economic Worthiness of Adjuvant Osimertinib Across EGFR+ NSCLC Subgroups: Brazilian Healthcare Analysis
Brazilian Journal of Oncology · 26.06.2026 · 22 (CP)
DOI: 10.1055/s-0046-1825463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brazilian Journal of Oncology, erschienen am 26.06.2026. Verfasst von Rodrigo Kraft Rovere und 2 weiteren Autor:innen.
Abstract (Originalsprache)
All articles of this category (opens in new window) Address for correspondence rodrigo kraft rovere (rodrigorovere@yahoo.com)
Introduction
Adjuvant osimertinib demonstrated unprecedented survival benefits in ADAURA across EGFR+ NSCLC stages IB-IIIA. Economic worthiness varies by stage, and cured patients avoid expensive advanced treatments including amivantamab and immunotherapy combinations, requiring stage-specific Brazilian economic evaluation.
Objective
To evaluate economic worthiness of adjuvant osimertinib across NSCLC subgroups in Brazilian healthcare, emphasizing avoided costs from expensive treatments that cured patients never require.
Method
Stage-stratified pharmacoeconomic model using ADAURA data and Brazilian costs over lifetime horizon. Costs included 3-year osimertinib (R$316,438/patient) and stage-specific avoided advanced treatments: amivantamab combinations, IMpower150 regimen, metastatic osimertinib, totaling R$400,000-1,200,000 per cured patient. Enhanced CONITEC threshold (R$122,000/QALY) applied for curative treatments.
Results
Stage IIIA showed strongest economic worthiness: ICER R$195,000/QALY with 68% cost-effectiveness probability, potential net savings R$150,000-400,000 per patient. Stage II: ICER R$285,000/QALY (42% cost-effective). Stage IB: ICER R$520,000/QALY (18% cost-effective). Five-year survival 88% vs 78% with hazard ratios 0.37, 0.63, 0.44 for stages IIIA, II, IB respectively. Avoided treatment costs per cured patient: amivantamab R$450,000-720,000, IMpower150 R$240,000-480,000.
Conclusion
Economic worthiness varies substantially by stage. Stage IIIA demonstrates clear justification with potential cost-savings, supporting immediate implementation. Stage II shows conditional worthiness requiring managed pricing. Stage IB needs substantial price reduction. Analysis supports staged implementation beginning with highest-benefit subgroups, transforming economics from expensive intervention to strategic investment in lung cancer cure. Publication History Article published online: 26 June 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil Bibliographical Record Rodrigo Kraft Rovere, Victor Hugo Fonseca De Jesus, Ana Claudia Galdino. Economic Worthiness of Adjuvant Osimertinib Across EGFR+ NSCLC Subgroups: Brazilian Healthcare Analysis. Brazilian Journal of Oncology 2026; 22. DOI: 10.1055/s-0046-1825463
Zitieren
APA
Rovere, R. K., Jesus, V. H. F. D., & Galdino, A. C. (2026). Economic Worthiness of Adjuvant Osimertinib Across EGFR+ NSCLC Subgroups: Brazilian Healthcare Analysis. Brazilian Journal of Oncology, 22(CP). https://doi.org/10.1055/s-0046-1825463
Vancouver
Rovere RK, Jesus VHFD, Galdino AC. Economic Worthiness of Adjuvant Osimertinib Across EGFR+ NSCLC Subgroups: Brazilian Healthcare Analysis. Brazilian Journal of Oncology. 2026;22(CP). doi:10.1055/s-0046-1825463
BibTeX
@article{Rovere2026,
author = {Rovere, Rodrigo Kraft and Jesus, Victor Hugo Fonseca De and Galdino, Ana Claudia},
title = {Economic Worthiness of Adjuvant Osimertinib Across EGFR+ NSCLC Subgroups: Brazilian Healthcare Analysis},
journal = {Brazilian Journal of Oncology},
year = {2026},
volume = {22},
number = {CP},
doi = {10.1055/s-0046-1825463}
}
EUVIMED